Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Abstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D122...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s13045-022-01299-z |
| _version_ | 1811248887402332160 |
|---|---|
| author | Toshio Fujino Kenichi Suda Takamasa Koga Akira Hamada Shuta Ohara Masato Chiba Masaki Shimoji Toshiki Takemoto Junichi Soh Tetsuya Mitsudomi |
| author_facet | Toshio Fujino Kenichi Suda Takamasa Koga Akira Hamada Shuta Ohara Masato Chiba Masaki Shimoji Toshiki Takemoto Junichi Soh Tetsuya Mitsudomi |
| author_sort | Toshio Fujino |
| collection | DOAJ |
| description | Abstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14. Methods The inhibitory effects of 300 drugs, including 33 MET-TKIs, were screened in Ba/F3 cells carrying METex14 plus MET D1228A/Y secondary mutations. The screen revealed four-candidate type II MET-TKIs (altiratinib, CEP-40783, foretinib and sitravatinib). Therefore, we performed further growth inhibitory assays using these four MET-TKIs plus cabozantinib and merestinib in Ba/F3 cells carrying MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations. We also performed analyses using Hs746t cell models carrying METex14 (with mutant allele amplification) with/without D1228X or Y1230X in vitro and in vivo to confirm the findings. Furthermore, molecular dynamics (MD) simulations were carried out to examine differences in binding between type II MET-TKIs. Results All 6 type II MET-TKIs were active against Y1230X secondary mutations. However, among these 6 agents, only foretinib showed potent activity against D1228X secondary mutations of the MET in the Ba/F3 cell and Hs746t in vitro model and Hs746t in vivo model, and CEP-40783 and altiratinib demonstrated some activity. MD analysis suggested that the long tail of foretinib plays an important role in binding D1228X MET through interaction with a residue at the solvent front (G1163). Tertiary G1163X mutations, together with L1195F/I and F1200I/L, occurred as acquired resistance mechanisms to the second-line treatment foretinib in Ba/F3 cell models. Conclusions The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230. |
| first_indexed | 2024-04-12T15:36:46Z |
| format | Article |
| id | doaj.art-91f7932bd36f4d28ab9a6bce380f3ecc |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-12T15:36:46Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-91f7932bd36f4d28ab9a6bce380f3ecc2022-12-22T03:26:56ZengBMCJournal of Hematology & Oncology1756-87222022-06-0115111410.1186/s13045-022-01299-zForetinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutationToshio Fujino0Kenichi Suda1Takamasa Koga2Akira Hamada3Shuta Ohara4Masato Chiba5Masaki Shimoji6Toshiki Takemoto7Junichi Soh8Tetsuya Mitsudomi9Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of MedicineAbstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X MET to propose an ideal sequential treatment after capmatinib/tepotinib treatment failure in NSCLC patients with METex14. Methods The inhibitory effects of 300 drugs, including 33 MET-TKIs, were screened in Ba/F3 cells carrying METex14 plus MET D1228A/Y secondary mutations. The screen revealed four-candidate type II MET-TKIs (altiratinib, CEP-40783, foretinib and sitravatinib). Therefore, we performed further growth inhibitory assays using these four MET-TKIs plus cabozantinib and merestinib in Ba/F3 cells carrying MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations. We also performed analyses using Hs746t cell models carrying METex14 (with mutant allele amplification) with/without D1228X or Y1230X in vitro and in vivo to confirm the findings. Furthermore, molecular dynamics (MD) simulations were carried out to examine differences in binding between type II MET-TKIs. Results All 6 type II MET-TKIs were active against Y1230X secondary mutations. However, among these 6 agents, only foretinib showed potent activity against D1228X secondary mutations of the MET in the Ba/F3 cell and Hs746t in vitro model and Hs746t in vivo model, and CEP-40783 and altiratinib demonstrated some activity. MD analysis suggested that the long tail of foretinib plays an important role in binding D1228X MET through interaction with a residue at the solvent front (G1163). Tertiary G1163X mutations, together with L1195F/I and F1200I/L, occurred as acquired resistance mechanisms to the second-line treatment foretinib in Ba/F3 cell models. Conclusions The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230.https://doi.org/10.1186/s13045-022-01299-z |
| spellingShingle | Toshio Fujino Kenichi Suda Takamasa Koga Akira Hamada Shuta Ohara Masato Chiba Masaki Shimoji Toshiki Takemoto Junichi Soh Tetsuya Mitsudomi Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation Journal of Hematology & Oncology |
| title | Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation |
| title_full | Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation |
| title_fullStr | Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation |
| title_full_unstemmed | Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation |
| title_short | Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation |
| title_sort | foretinib can overcome common on target resistance mutations after capmatinib tepotinib treatment in nsclcs with met exon 14 skipping mutation |
| url | https://doi.org/10.1186/s13045-022-01299-z |
| work_keys_str_mv | AT toshiofujino foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT kenichisuda foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT takamasakoga foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT akirahamada foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT shutaohara foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT masatochiba foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT masakishimoji foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT toshikitakemoto foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT junichisoh foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation AT tetsuyamitsudomi foretinibcanovercomecommonontargetresistancemutationsaftercapmatinibtepotinibtreatmentinnsclcswithmetexon14skippingmutation |